RAF265

08/01/2017 - "To establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety profile, and anti-tumor efficacy of RAF265. "
03/01/2011 - "Our results support the use of FDG PET in clinical trials with RAF265 to assess early tumor response. "
04/15/2012 - "Tumor implants from 7 of 17 patients (41%) responded to RAF265 treatment with more than 50% reduction in tumor growth. "
04/15/2012 - "Tumors that grew in mice (17 of 34) were evaluated for response to RAF265 (40 mg/kg, every day) over 30 days. "
03/01/2011 - "RAF265 also inhibited FDG accumulation in tumor xenografts after 1 day of drug treatment. "

08/01/2017 - "A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status."
04/15/2012 - "The purpose of this preclinical study was to determine the effectiveness of RAF265, a multikinase inhibitor, for treatment of human metastatic melanoma and to characterize traits associated with drug response. "
09/10/2015 - "Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma."
04/15/2012 - "A subpopulation of human melanoma tumors responds to RAF265 and can be characterized by gene mutation and gene expression profiles."
04/15/2012 - "RAF265 inhibits the growth of advanced human melanoma tumors."

02/01/2013 - "We have found a new therapeutic application for RAF265 as an inhibitory agent of osteoclastogenesis and OC function, which might be useful for the treatment of skeletal disorders associated with increased bone resorption."

08/01/2014 - "Aim of this study was to characterized the preclinical effectiveness of novel promising drugs, RAF265, SB590885 and ZSTK474 in 3 thyroid cancer cell lines (BCPAP, K1, 8505C). "
08/01/2014 - "The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways."
10/15/2011 - "RAF265, an ATP-competitive pan-RAF inhibitor active against VEGFR2, and BEZ-235, a PI3K inhibitor also active against Torc1 and Torc2, were tested alone and in combination in a panel of thyroid cancer lines. "

04/11/2015 - "Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma."